Co-enzyme Q10 And Remacemide Evaluation in Huntington Disease (CARE-HD)

Co-enzyme Q10 And Remacemide Evaluation in Huntington Disease (CARE-HD)

« return to clinical trials
HUNTINGTON'S DISEASE CLINIC

CARE-HD is a drug trial for symptomatic individuals done in collaboration with the Huntington Study Group, University of Rochester, New York, USA.

Overview

The purpose of this trial is to analyse the effect of remacemide and co-enzyme Q10 (CoQ10) on the progression of HD. Excess activity of glutamate in the brain is postulated to be involved in neuron death in HD. Remacemide decreases activity of glutamate on target cells. Co-enzyme Q10 is an anti-oxidant, that helps neurons to cope with the stress of excessive glutamate.

Design

  • 347 participants in Canada and the US (12 at UBC)

  • Double-blind, placebo-controlled trial

    • Group 1: Remacemide

    • Group 2: Co-enzyme Q10

    • Group 3: Remacemide + Co-enzyme Q10

    • Group 4: Placebo

  • 11 visits over 31 months

Outcome

This study has been completed and results showed that remacemide has no benefit for persons in the early stages of HD. The study results about CoQ10 are inconclusive.

Site Investigation Team

  • Dr. Lynn Raymond (site investigator)

  • Dr. Elisabeth Almqvist (site co-ordinator)

For further information, please call the site investigation team at +1 (604) 822-7738.